Atmo Biosciences
PrivateLast Round
Secondary
Sep 25, 2023
Est. Valuation
$9.58M
Total Funding Raised
$15.94M
Company Overview
Atmo Biosciences is a digital health company that develops an ingestible gas-sensing capsule providing real-time insights into gut health and microbiome function.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Health IoT, Clinical Trials, Healthcare Analytics
Business Model
B2B
Customer Profile
Hardware Sales, Usage-Based SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Atmo Biosciences Comparables
Compare Atmo Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alimetry Ltd. | 85% | |
| Endiatx | 83% | |
| EnteraSense | 79% |
For institutional investors. Book with your work email.
Atmo Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Secondary | Sep 25, 2023 | ||||
| Series B | Mar 30, 2023 | ||||
| Series A | Sep 15, 2021 | ||||
| Grant | Jun 30, 2021 | ||||
| Grant | Jul 20, 2020 | ||||
Seed | Jun 2, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Atmo Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioMedTech Horizons | Grant |
| Alium Capital | Series A |
| ANDHealth | Seed |
| Australian Government | Grant |
| Breakthrough Victoria | Secondary |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 9, 2025
Monthly visitors grew 111% MoM, reaching 3.8K.
- Apr 15, 2025
Monthly visitors increased 54% MoM, reaching 2K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingAug 14, 2026
Atmo Biosciences, a Melbourne-based startup developing ingestible capsules to assess gut health, raises $12M in a new funding round reportedly reducing its valuation from $70 million to $25 million, with an unnamed family office, Breakthrough Victoria and former Cochlear CEO Chris Roberts participating.
For institutional investors. Book with your work email.
Atmo Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Atmo Biosciences's valuation, stock price, and market status.
Is Atmo Biosciences a public or private company?
Atmo Biosciences is a private company.
What is the current stock price of Atmo Biosciences?
Atmo Biosciences is a private company, so its shares have no public market price. Caplight tracks Atmo Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Atmo Biosciences worth (valuation)?
Atmo Biosciences's valuation is estimated at $9.6M based on funding round data.
Can I buy Atmo Biosciences stock?
Atmo Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Atmo Biosciences's last funding round?
Atmo Biosciences's most recent funding round was Secondary on September 25, 2023.
Who are the main investors in Atmo Biosciences?
Key investors in Atmo Biosciences include Alium Capital, Breakthrough Victoria.
Will Atmo Biosciences IPO soon?
No public IPO plans have been announced for Atmo Biosciences.
How can I track Atmo Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Atmo Biosciences's shares on secondary markets.